secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-162578
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026
--------------------------------------------------------------------------------

- Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.
- Safety (n=64): no DLTs, no Grade 4/5 AEs, no treatment-related discontinuations, no renal complications.
- 18 of 25 patients (72%) progression-free in Cohorts 1 and 2 first half as of March 4, 2026 data cutoff.
- Initial efficacy data from additional 23 Cohort 2 and first 8 Cohort 3 patients expected later 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/0001193125-26-162578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/catx-20260418.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-162578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer